Roche launches new global Certified Provider Program for Target Enrichment in Genomic Sequencing
11 APRIL 17
Pleasanton, CA, April 11, 2017 – Roche (SIX: RO, ROG; OTCQX: RHHBY) is pleased to announce the Certified Service Provider (CSP) program for SeqCap EZ Target Enrichment Systems utilizing Kapa library preparation kits. The program involves rigorous training and certification procedures, which when completed, provide genomic service providers a certification ensuring that consistent and robust results can be achieved for their customers using Roche’s SeqCap EZ Target Enrichment products.
To date, the first genomics service providers in Spain, Centro Nacional de Análisis Genómico and China, Genergy Bio Technology have achieved certification in the program which will help meet their customers’ target enrichment needs for both basic and clinical research applications.
“This alliance will help researchers to experiment with a variety of applications and designs without a large investment, and have greater confidence in the results provided,” said Neil Gunn, Head of Roche Sequencing Solutions.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.